360° Coverage : WSJ Attack on Sham Surgery Is About Healthy Profits, Not Patients

2 Updates

WSJ Attack on Sham Surgery Is About Healthy Profits, Not Patients

Feb 20 2014, 7:09pm CST | by

In an op-ed piece in the  Wall Street Journal Scott Gottlieb, a former FDA official under George W. Bush, argues that the FDA should stop requiring medical device companies to use sham...

Filed under: news

 
 
 

35 weeks ago

WSJ Attack on Sham Surgery Is About Healthy Profits, Not Patients

Feb 20 2014, 7:09pm CST | by

In an op-ed piece in the  Wall Street Journal Scott Gottlieb, a former FDA official under George W. Bush, argues that the FDA should stop requiring medical device companies to use sham procedures when they test certain new products. To support his argument he uses the example of renal denervation, a once highly promising new technology for lowering blood pressure. Unfortunately, Gottlieb extracts exactly the wrong lesson from this story, because the renal denervation story is a perfect example of why sham procedures can be both necessary and more ethical than any alternative.

At first glance it’s hard to disagree with Gottlieb. The idea that patients would receive an invasive surgical procedure that could do no good appears abhorrent. “Research that introduces harm or risk with no opportunity for benefit would seem to conflict with the principles governing research on humans,” writes Gottlieb.

But the same exact words could and should be used to describe medical devices with no proven benefit. In such cases, however, instead of the relatively small number of patients potentially exposed to harm in clinical studies, the number of patients exposed to harm in the real world may be larger by many orders of magnitude.

Let’s examine this issue using the same example used by Gottlieb: renal denervation. In case you haven’t been following this story, for the last few years renal denervation– the zapping of the renal artery with electric energy to lower blood pressure– has been widely considered to be one of the most exciting and promising new medical technologies around. Based on preliminary– and uncontrolled– studies renal denervation was thought to consistently lower blood pressure by an astounding 25-30 mm Hg and was hailed by many hypertension experts as a potential breakthrough cure for people who had persistently and dangerously high blood pressure even after taking several blood pressure pills.

Then reality intruded. Medtronic announced last month that its pivotal trial of renal denervation had not met its primary endpoint. It became clear that renal denervation was neither a cure nor a breakthrough. Although the details of the trial have not been revealed, the underlying cause of the trial’s failure is fairly well understood. Last summer a few skeptical British researchers carefully examined the underlying science and concluded– contrary to what industry and the experts had been saying– that the true blood pressure lowering effect of renal denervation wold be much smaller than predicted. And the reason was simple: because all the early studies had been either uncontrolled or poorly controlled, the companies and the researchers had greatly overestimated the true effect of renal denervation. The Medtronic trial, by contrast, was much more rigorous, in part because it included the notorious sham procedures decried by Gottlieb.

As Gottlieb notes, renal denervation “is already available in Europe, where regulators approved it based on traditional studies.” Gottlieb fails to notice how this undercuts his point. After all, many thousands of people in Europe have received a device from which they may have received no or little benefit and may have experienced harm. But this doesn’t seem to concern Gottlieb. Here, writing about the effect of well-controlled trials, is what does concern Gottlieb:

All of this raises development costs—and it encourages firms to skip the U.S. market and commercialize new products overseas. This can suppress innovation. When a sham trial doesn’t produce positive results, the company may have exhausted its resources and have no capital left to refine a good idea into a beneficial product.

But, as the renal denervation story demonstrates, the trial didn’t “suppress innovation.” Instead it showed that the so-called “innovation” was, well, a sham.

Although he waves the flag for ethics, it’s clear that what really motivates Gottlieb to stand up and salute is business profits. He’s far more interested in the health of businesses than he is in the health of patients. If he were actually interested in the welfare of patients he would pay attention to the medical details of his examples. But instead his real concern seems to be the health of the bottom line.

This isn’t the first time Gottlieb has confused ethics and economics. In 2012 he wrote about another new medical technology, transcatheter aortic valve replacement (TAVR), and argued that the FDA and CMS had prevented the American public from benefiting from the procedure. As I wrote then, Gottlieb completely ignored the complex issues of the story, spinning an untrue but compelling tale in which the forces of government were preventing desperately sick people from getting a new life-saving therapy.

It seems clear that Gottlieb has very little interest in a serious discussion of clinical trials or the best way to test and introduce new medical technology. What he really wants is to provide a basis for campaign slogans that undermine the FDA and government involvement in medicine. It doesn’t matter that sham surgery is a complex issue or that TAVR had as much potential danger as benefit. It’s easy to score polemical points by scaring people, telling them that they will be subject to harmful procedures or that their government is preventing them from getting life-saving treatments. It’s much harder, and less politically advantageous, to consider the full complexity of these issues.

Update:

Sanjay Kaul sent the following comment:

“Those who cannot remember the past are condemned to repeat it”.

There are many examples where the “scam” of some device-based therapies has been exposed by the “sham” procedure. How can anyone forget the classic examples of laser TMR (TransMyocardial Revascularization) or Pacemaker for hypertrophic cardiomyopathy, both touted as breakthrough interventions. It would not surprise me one bit if RF ablation for atrial fibrillation ends up with a similar fate!

Source: Forbes Business

 
Update
2

8 weeks ago

Khazanah throws MAS RM6b lifeline

Aug 29 2014 5:01pm CDT | Source: Business Times Singapore

August 30, 2014 1:15 AMKHAZANAH Nasional will inject RM6 billion (SS$2.4 billion) over three years to resuscitate loss-making Malaysia Airlines (MAS) under a recovery plan that includes even an Act of Parliament. Other key moves are migrating its operations, assets and liabilities to a new company (NewCo) and slashing the work ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 
Update
1

8 weeks ago

MAS posts loss of RM307m for Q2

Aug 28 2014 5:00pm CDT | Source: Business Times Singapore

August 29, 2014 1:13 AMMALAYSIA Airlines (MAS) registered a loss of RM307 million (S$122 million) for the second quarter to end-June, but warned of worse to come in the second half when the "full financial impact of the double tragedies of MH370 a ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

World Bank approves $75 mn for pastoralists in Horn of Africa
Nairobi, Oct 26 (IANS) The World Bank has approved an additional credit of $75 million to improve the livelihoods and resilience of pastoralists in the Horn of Africa.
 
 
Slovakia to provide further financial help in fighting Ebola
Bratislava, Oct 26 (IANS) Slovakia planned to provide some 90,000 euros ($114,000) to countries affected by Ebola to help with the construction of field hospitals, foreign ministry said Saturday.
 
 
Mauritania closes border with Mali after Ebola death
Nouakchott, Oct 26 (IANS) Mauritania has closed its border with Mali after an Ebola death was confirmed in the border area this week, a health official said Saturday.
 
 
Number of Ebola cases crosses 10,000: WHO
Geneva, Oct 25 (IANS/EFE) The World Health Organisation (WHO) confirmed Saturday that the number of Ebola cases has risen to more than 10,000 in the eight affected countries, two of which, Nigeria and Senegal, had recently been declared free of the virus.
 
 
 

Latest from the Network

Second MERS case reported in Qatar
Doha, Oct 23 (IANS) A 43-year-old man in Qatar has tested positive for Middle East Respiratory Syndrome (MERS) in the second confirmed case of the deadly virus in 10 days, media reported Thursday. The patient had...
Read more on Business Balla
 
Two people die in Pakistan bomb blast
Islamabad, Oct 23 (IANS) At least two people were killed and 12 others injured in an explosion that took place in Pakistan's Balochistan province Thursday, media reported. The bomb was planted on a motorcycle, Dawn...
Read more on Politics Balla
 
Trott extends contract with Warwickshire till 2017
London, Oct 23 (IANS) England batsman Jonathan Trott, whose mental issues led to his abrupt departure from last winter's Ashes tour, has confirmed his successful comeback to competitive cricket by signing a new three-...
Read more on Sport Balla
 
Srikanth, Kashyap big movers in BWF rankings
Kuala Lumpur, Oct 23 (IANS) Indian men shuttlers Kidambi Srikanth and Parupalli Kashyap jumped seven places each in the latest Badminton World Federation (BWF) rankings released Thursday while Olympic bronze medallist...
Read more on Sport Balla
 
Alvin Stardust dead
London, Oct 23 (IANS) English singer Alvin Stardust died after a short illness. He was 72. Stardust's manager confirmed the news about his demise Thursday, reports mirror.co.uk. He was recently diagnosed with...
Read more on Celebrity Balla
 
Indian man reunited with family after 40 years
Dubai, Oct 23 (IANS) An Indian man, who had disappeared from his hometown in Kerala nearly 40 years ago, has been found by his family at a hospital in Dubai in the UAE, a newspaper report said. Now in his 60s, Abdulla...
Read more on Politics Balla
 
Srikanth, Kashyap, Saina rise in world rankings
Kala Lumpur, Oct 23 (IANS) Indian men shuttlers Kidambi Srikanth and Parupalli Kashyap jumped seven places each in the latest released Badminton World Federation (BWF) rankings Thursday while Olympic bronze medallist...
Read more on Sport Balla
 
Flintoff signs for Big Bash side Brisbane Heat
Brisbane, Oct 23 (IANS) Former England captain and all-rounder Andrew Flintoff, who retired from international cricket in 2009, Wednesday confirmed that he will play for Brisbane Heat in the Big Bash League (BBL) this...
Read more on Sport Balla
 
OPEC daily basket price falls again
Vienna, Oct 23 (IANS/WAM) The basket of 12 crude oils of the Organization of Petroleum Exporting Countries (OPEC) closed at $81.94 a barrel Wednesday compared to $82.09 Tuesday, the OPEC Secretariat said. The new OPEC...
Read more on Business Balla
 
Lopez to sign multi-million dollar deal?
Los Angeles, Oct 23 (IANS) Singer-actress Jennifer Lopez is reportedly in the final stages of securing a multi-million dollar deal to perform in Las Vegas. The 45-year-old is being offered $350,000 per show at The...
Read more on Celebrity Balla